GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cohance Lifesciences Ltd (NSE:SUVENPHAR) » Definitions » Institutional Ownership

Cohance Lifesciences (NSE:SUVENPHAR) Institutional Ownership : 22.44% (As of May. 11, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Cohance Lifesciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cohance Lifesciences's institutional ownership is 22.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cohance Lifesciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cohance Lifesciences's Float Percentage Of Total Shares Outstanding is 0.00%.


Cohance Lifesciences Institutional Ownership Historical Data

The historical data trend for Cohance Lifesciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cohance Lifesciences Institutional Ownership Chart

Cohance Lifesciences Historical Data

The historical data trend for Cohance Lifesciences can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 22.74 22.78 22.35 22.35 22.19 22.56 22.55 22.63 22.34 22.44

Cohance Lifesciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cohance Lifesciences Business Description

Traded in Other Exchanges
Address
No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081
Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Cohance Lifesciences Headlines

No Headlines